Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Gastrointestinal Stromal Tumor | Research

Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature

Authors: Jiaqi Yan, Xin He, Chaoyong Shen, Yan Zou, Huijiao Chen, Yuan Tang

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Aims

Primary double KIT/PDGFRA mutations are very rare in gastrointestinal stromal tumours (GISTs) but have not been comprehensively studied to date. In the present study, we investigated the clinicopathologic and genetic features of eight cases of primary double-mutant GISTs, and we reviewed the literature.

Methods and results

The tumours occurred in six males and two females (age range 57–83 years) and involved the small intestine (n = 4), stomach (n = 2), rectum (n = 1) and retroperitoneum (n = 1). Clinical manifestations were variable, ranging from indolent (no symptoms) to aggressive disease (tumour rupture and haemorrhage). All patients underwent surgical excision, and six of them were treated with imatinib. No one experienced recurrence or other complications during the follow-up time (10 to 61 months). Histologically, all the tumours exhibited mixed cell types, accompanied by variable interstitial changes. KIT mutations were detected in all cases, and the majority of them were present in different exons (n = 5). No PDGFRA exon 12, 14 or 18 mutations were found. All the mutations were validated by next-generation sequencing, and two additional variants with comparatively low allelic fractions were identified in one case. Two of the cases had available allele distribution data, one with an in cis compound mutation and the other with an in trans compound mutation.

Conclusion

Primary double-mutant GISTs have distinctive clinicopathologic and mutational features. Studies of more cases are necessary for a better understanding of these tumours.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classfication of tumours of soft tissue and bone. 4th ed. Lyon: LARC Press; 2013. pp. 164–7. Fletcher CDM, Bridge JA, Hogendoorn PCW, et al. WHO classfication of tumours of soft tissue and bone. 4th ed. Lyon: LARC Press; 2013. pp. 164–7.
2.
go back to reference Lee JH, Kim Y, Choi JW, et al. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. J Gastrointestin Liver Dis. 2013;22:413–8.PubMed Lee JH, Kim Y, Choi JW, et al. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis. J Gastrointestin Liver Dis. 2013;22:413–8.PubMed
3.
go back to reference Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010;14:42–50.CrossRefPubMed Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med. 2010;14:42–50.CrossRefPubMed
4.
go back to reference Wong NA. Gastrointestinal stromal tumours-an update for histopathologists. Histopathology. 2011;59:807–21.CrossRefPubMed Wong NA. Gastrointestinal stromal tumours-an update for histopathologists. Histopathology. 2011;59:807–21.CrossRefPubMed
5.
go back to reference Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764–74.CrossRefPubMed Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24:4764–74.CrossRefPubMed
6.
go back to reference Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34:1480–91.CrossRefPubMed Rossi S, Gasparotto D, Toffolatti L, et al. Molecular and clinicopathologic characterization of gastrointestinal stromal tumors (GISTs) of small size. Am J Surg Pathol. 2010;34:1480–91.CrossRefPubMed
7.
go back to reference Conca E, Miranda C, Dal Col V, et al. Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib. Mol Oncol. 2013;7:756–62.CrossRefPubMedPubMedCentral Conca E, Miranda C, Dal Col V, et al. Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib. Mol Oncol. 2013;7:756–62.CrossRefPubMedPubMedCentral
8.
go back to reference Kalfusova A, Linke Z, Kalinova M, et al. Gastrointestinal stromal tumors-summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects. Pathol Res Pract. 2019;215(12):152708.CrossRefPubMed Kalfusova A, Linke Z, Kalinova M, et al. Gastrointestinal stromal tumors-summary of mutational status of the primary/secondary KIT/PDGFRA mutations, BRAF mutations and SDH defects. Pathol Res Pract. 2019;215(12):152708.CrossRefPubMed
9.
go back to reference Wong NA, Taniere P, Walsh S, et al. Gastrointestinal stromal tumor with multiple primary tyrosine kinase mutations-clinicopathologic and molecular characterization. Appl Immunohistochem Mol Morphol. 2019;27:461–5.CrossRefPubMed Wong NA, Taniere P, Walsh S, et al. Gastrointestinal stromal tumor with multiple primary tyrosine kinase mutations-clinicopathologic and molecular characterization. Appl Immunohistochem Mol Morphol. 2019;27:461–5.CrossRefPubMed
10.
go back to reference Haefliger S, Marston K, Juskeviciu D, et al. Molecular Profile of gastrointestinal stromal tumors in sixty-eight patients from a single Swiss Institution. Pathobiology. 2020;87:171–8.CrossRefPubMed Haefliger S, Marston K, Juskeviciu D, et al. Molecular Profile of gastrointestinal stromal tumors in sixty-eight patients from a single Swiss Institution. Pathobiology. 2020;87:171–8.CrossRefPubMed
11.
go back to reference Bombac A, Zakotnik B, Bucic M, et al. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours. Int J Oncol. 2020;56:1468–78.PubMedPubMedCentral Bombac A, Zakotnik B, Bucic M, et al. Mutational spectrum and classification of novel mutations in patients with metastatic gastrointestinal stromal tumours. Int J Oncol. 2020;56:1468–78.PubMedPubMedCentral
12.
go back to reference Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and variant interpretation for Cancer Consortium (VICC). Genet Med. 2022;24:986–98.CrossRefPubMed Horak P, Griffith M, Danos AM, et al. Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and variant interpretation for Cancer Consortium (VICC). Genet Med. 2022;24:986–98.CrossRefPubMed
13.
go back to reference Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.CrossRefPubMed Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.CrossRefPubMed
14.
go back to reference Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.CrossRefPubMed Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.CrossRefPubMed
15.
go back to reference Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–89.CrossRefPubMed Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477–89.CrossRefPubMed
16.
go back to reference Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68.CrossRefPubMed Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68.CrossRefPubMed
17.
go back to reference WHO Classification of Tumours Editorial Board. WHO classification of tumours of soft tissue and bone tumours. Revised 5th ed. Lyon: IARC; 2020. WHO Classification of Tumours Editorial Board. WHO classification of tumours of soft tissue and bone tumours. Revised 5th ed. Lyon: IARC; 2020.
18.
go back to reference Jumniensuk C, Charoenpitakchai M. Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis. World J Surg Oncol. 2018;16:231.CrossRefPubMedPubMedCentral Jumniensuk C, Charoenpitakchai M. Gastrointestinal stromal tumor: clinicopathological characteristics and pathologic prognostic analysis. World J Surg Oncol. 2018;16:231.CrossRefPubMedPubMedCentral
19.
go back to reference Li J, Zhang H, Chen Z, et al. Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a chinese population. Int J Clin Exp Pathol. 2015;8:15969–76.PubMedPubMedCentral Li J, Zhang H, Chen Z, et al. Clinico-pathological characteristics and prognostic factors of gastrointestinal stromal tumors among a chinese population. Int J Clin Exp Pathol. 2015;8:15969–76.PubMedPubMedCentral
20.
go back to reference Cao H, Zhang Y, Wang M, et al. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Chin Med J. 2010;123:131–6.PubMed Cao H, Zhang Y, Wang M, et al. Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease. Chin Med J. 2010;123:131–6.PubMed
21.
go back to reference Tazawa K, Tsukada K, Makuuchi H, et al. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int. 1999;49:786–98.CrossRefPubMed Tazawa K, Tsukada K, Makuuchi H, et al. An immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int. 1999;49:786–98.CrossRefPubMed
22.
go back to reference Lopes LF, Ojopi EB, Bacchi CE. Gastrointestinal stromal tumor in Brazil: clinicopathology, immunohistochemistry, and molecular genetics of 513 cases. Pathol Int. 2008;58:344–52.CrossRefPubMed Lopes LF, Ojopi EB, Bacchi CE. Gastrointestinal stromal tumor in Brazil: clinicopathology, immunohistochemistry, and molecular genetics of 513 cases. Pathol Int. 2008;58:344–52.CrossRefPubMed
23.
24.
go back to reference Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13:93–107.CrossRefPubMed Szucs Z, Thway K, Fisher C, et al. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017;13:93–107.CrossRefPubMed
25.
go back to reference Vu HA, Xinh PT, Kikushima M, et al. A recurrent duodenal gastrointestinal stromal tumor with a frameshift mutation resulting in a stop codon in KIT exon 13. Genes Chromosomes Cancer. 2005;42:179–83.CrossRefPubMed Vu HA, Xinh PT, Kikushima M, et al. A recurrent duodenal gastrointestinal stromal tumor with a frameshift mutation resulting in a stop codon in KIT exon 13. Genes Chromosomes Cancer. 2005;42:179–83.CrossRefPubMed
26.
go back to reference Yan C, Zhao C, Yang K, et al. Rare c-KIT c.1926delA and c.1936T > G mutations in exon 13 define Imatinib Resistance in gastrointestinal stromal tumors and Melanoma Patients: Case Reports and Cell experiments. Front Mol Biosci. 2022;9:730213.CrossRefPubMedPubMedCentral Yan C, Zhao C, Yang K, et al. Rare c-KIT c.1926delA and c.1936T > G mutations in exon 13 define Imatinib Resistance in gastrointestinal stromal tumors and Melanoma Patients: Case Reports and Cell experiments. Front Mol Biosci. 2022;9:730213.CrossRefPubMedPubMedCentral
27.
go back to reference Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.CrossRefPubMedPubMedCentral Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–9.CrossRefPubMedPubMedCentral
28.
go back to reference McDonnell K, Betz B, Fullen D, et al. V559A and N822I double KIT mutant melanoma with predictable response to imatinib? Pigment Cell Melanoma Res. 2011;24:390–2.CrossRefPubMed McDonnell K, Betz B, Fullen D, et al. V559A and N822I double KIT mutant melanoma with predictable response to imatinib? Pigment Cell Melanoma Res. 2011;24:390–2.CrossRefPubMed
29.
go back to reference Lasota J, vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest. 2007;87:1029–41.CrossRefPubMed Lasota J, vel Dobosz AJ, Wasag B, et al. Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Lab Invest. 2007;87:1029–41.CrossRefPubMed
30.
go back to reference Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol. 2009;14:143–9.CrossRefPubMed Nishida T, Takahashi T, Nishitani A, et al. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol. 2009;14:143–9.CrossRefPubMed
Metadata
Title
Clinicopathological and mutational characteristics of primary double mutant gastrointestinal stromal tumor: a single center study with review of the literature
Authors
Jiaqi Yan
Xin He
Chaoyong Shen
Yan Zou
Huijiao Chen
Yuan Tang
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10684-x

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine